Nyxoah Says DREAM US Pivotal Study Meets Primary Endpoints
Portfolio Pulse from Benzinga Newsdesk
Nyxoah announced that its DREAM US pivotal study met its primary endpoints. CEO Olivier Taelman stated they are finalizing the PMA application's fourth module and anticipate launching Genio in the U.S, pending FDA approval.
March 19, 2024 | 8:06 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Nyxoah's successful DREAM US study results and the nearing completion of the PMA application for Genio could significantly boost investor confidence.
The positive outcome of the DREAM US study and the progress towards FDA approval for Genio are critical milestones for Nyxoah. These developments are likely to be viewed positively by investors, potentially leading to an increase in stock price in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100